Skip Navigation


NDT Advance Access originally published online on February 9, 2006
Nephrology Dialysis Transplantation 2006 21(7):1992-1993; doi:10.1093/ndt/gfl028
This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
21/7/1992    most recent
gfl028v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ohtake, T.
Right arrow Articles by Moriya, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ohtake, T.
Right arrow Articles by Moriya, H.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2006]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org


Case Report

Ticlopidine-induced lupus with renal involvement

Takayasu Ohtake1, Shuzo Kobayashi1, Koji Okamoto1, Machiko Oka1, Kyoko Maesato1, Takeo Yasu2 and Hidekazu Moriya1

1 Department of Nephrology, and Kidney & Dialysis Center and 2 Department of Pharmacy, Shonan Kamakura General Hospital, 1202-1 Yamazaki, Kamakura, 247-8533, Japan

Correspondence and offprint requests to: Takayasu Ohtake, MD, PhD, Department of Nephrology and Kidney and Dialysis Center, Shonan Kamakura General Hospital, 1202-1 Yamazaki, Kamakura, 247-8533, Japan. Email: ohtake{at}shonankamakura.or.jp

Keywords: drug-induced lupus; mesangial proliferative glomerulonephritis; renal involvement; systemic lupus erythematosus; ticlopidine



   Introduction
 Top
 Introduction
 Case
 References
 
Ticlopidine hydrochloride is a platelet aggregation inhibitor that is used for the prevention of vascular thrombosis. So far, only six cases of ticlopidine-induced lupus have been documented in the literature [1–3]. We report here a first case of ticlopidine-induced lupus with renal involvement.



   Case
 Top
 Introduction
 Case
 References
 
A 71-year-old Japanese man was admitted on 24 January 2005 because of fever, arthralgia, chest pain and dyspnea. He had suffered from cerebral infarction 2 years previously, and had been treated with ticlopidine (200 mg/day) since then. On admission, his temperature was 37.4°C, and C-reactive protein (CRP) was elevated to 19.7 mg/dl. Renal function was normal, and there was no proteinuria or microhaematuria. Chest X-ray films revealed bilateral pleural effusion, and an aspirate indicated it as exudates. Within 2 weeks of admission, proteinuria (1.5 g/day), and microhaematuria developed. Laboratory tests showed a positive anti-nuclear antibody (ANA, 1:640), a positive anti-double-strand DNA IgG antibody (ds-DNA-Ab, 41.8 IU/l, reference range: <20 IU/l), and a high anti-single-strand DNA IgG antibody (ss-DNA-Ab, 189.4 AU/ml, reference range: <40 arbitrary units/ml). Lupus erythematosus cells in the pleural aspirate and a high titre of serum anti-H2A/H2B histone antibody (>100 U/ml, normal reference range: <20 U/ml) were detected. Serum complement levels were within the normal range. Finally, he was diagnosed as having ticlopidine-induced lupus.

Renal biopsy was performed after discontinuation of ticlopidine. Seven glomeruli were seen on light microscopy, and glomerular changes were mild with segmental proliferation of mesangial cells and matrix. Mild tubular atrophy, interstitial fibrosis and monocyte infiltration were also seen. Immunofluorescent microscopy revealed positive staining for C3 and IgG, and C1q in the mesangial area. Electron microscopy revealed electron-dense mesangial and subendothelial deposits. Since withdrawal of the drug did not improve his symptoms and laboratory abnormalities, a low dose of oral prednisolone (15 mg/day) was administered. Two months later, both CRP and ss-DNA-Ab improved to the normal range, and proteinuria decreased to 0.3 g/day. His pleuritic chest pain and pleural effusions completely resolved.

In ticlopidine-induced lupus, arthralgia was found in all and serositis was found in half of the patients [1–3]. The interval from starting drug ingestion to the onset has varied from 1 month to 2 years. Haematological, skin or central nervous system involvement has never been seen [1–3]. The mechanism of drug-induced lupus has not been fully elucidated. Acetylation capacity is thought to be related [4], but there is no acetylation step in the metabolism of ticlopidine. Withdrawal of the suspected drug usually improves the clinical manifestations. However, steroids may be used in patients who have drug-induced lupus with rapid progression or severe pathological damages [5]. The therapeutic strategy may need to be considered on a case-by-case basis, depending on the pathological and clinical features of each patient.

Conflict of interest statement. None declared.



   References
 Top
 Introduction
 Case
 References
 

  1. Matsuda M, Ooura N, Hattori T, Miki J, Tabata K. A case of drug-induced lupus possibly due to ticlopidine. Naika 2001; 88: 181–183 (in Japanese)
  2. Spiera RF, Berman RS, Werner AJ, Spiera H. Ticlopidine-induced lupus. A report of 4 cases. Arch Intern Med 2002; 162: 2240–2243[Abstract/Free Full Text]
  3. Okada H, Kikuta T, Watanabe Y, Kanno Y, Sugahara S, Suzuki H. Ticlopidine induces lupus in a hemodialysis patient. Nephrol Dial Transplant 2004; 19: 2685–2686[Free Full Text]
  4. Rich MW. Drug-induced lupus. The list of culprits grows. Postgrad Med 1996; 100: 299–308[Medline]
  5. Prasad GVR, Bastacky S, Johnson JP. Propylthiouracil-induced diffuse proliferative lupus nephritis: review of immunological complications. J Am Soc Nephrol 1997; 8: 1205–1210[Abstract]
Received for publication: 25.11.05
Accepted in revised form: 23. 1.06


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
21/7/1992    most recent
gfl028v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ohtake, T.
Right arrow Articles by Moriya, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ohtake, T.
Right arrow Articles by Moriya, H.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?